Element contents
Series: Elements in Molecular Oncology
EGFR-Directed Therapy in Lung Cancer
Published online by Cambridge University Press: 05 January 2023
Summary
Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a clinically important driver alteration affecting approximately one-third of lung cancer patients. Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have evolved over the last decade from first-generation reversible tyrosine kinase inhibitors (TKI) to third-generation irreversible TKIs, of which osimertinib has been the widely accepted as first-line therapy. Despite survival improvement seen with osimertinib and its efficacy against acquired T790M mutation, resistance through on-target and off-target pathways eventually develop. This Element describes the structural biology and pathophysiology of EGFR-mutant NSCLC and discusses past, current, and future treatment options in the metastatic, neoadjuvant, and adjuvant settings. It describes the biology and recently approved treatment for EGFR-exon 20 insertion mutation and the treatment for the uncommon exon 18 (G719X), 20 (S768I), and 21 (L861Q) mutations. It also outlines the promising clinical applications of circulating tumor DNA (ctDNA).
Information
- Type
- Element
- Information
- Series: Elements in Molecular OncologyOnline ISBN: 9781009342285Publisher: Cambridge University PressPrint publication: 26 January 2023
References
Carpenter, G., King, L. Jr., and Cohen, S., Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro. Nature, 1978. 276(5686): pp. 409–10.Google Scholar
Lemmon, M. A. and Schlessinger, J., Cell signaling by receptor tyrosine kinases. Cell, 2010. 141(7): pp. 1117–34.Google Scholar
Zhang, X., et al., An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell, 2006. 125(6): pp. 1137–49.Google Scholar
Li, N., et al., Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. Nature, 1993. 363(6424): pp. 85–8.Google Scholar
Gale, N. W., et al., Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras. Nature, 1993. 363(6424): pp. 88–92.Google Scholar
Harmer, S. L. and DeFranco, A. L., Shc contains two Grb2 binding sites needed for efficient formation of complexes with SOS in B lymphocytes. Mol Cell Biol, 1997. 17(7): pp. 4087–95.Google Scholar
Uribe, M. L., Marrocco, I., and Yarden, Y., EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance. Cancers (Basel), 2021. 13(11): 2748.Google Scholar
Wee, P. and Wang, Z., Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel), 2017. 9(5): 52.Google Scholar
Mohrherr, J., et al., STAT3: Versatile functions in non-small cell lung cancer. Cancers (Basel), 2020. 12(5): 107.Google Scholar
Costa, D. B., et al., BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med, 2007. 4(10): pp. 1669–79; discussion p. 1680.Google Scholar
Kobayashi, S., et al., Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res, 2006. 66(23): pp. 11389–98.Google Scholar
Zhang, Z., et al., Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis, 2010. 31(4): pp. 577–86.Google Scholar
Owens, D. M. and Keyse, S. M., Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene, 2007. 26(22): pp. 3203–13.Google Scholar
Chitale, D., et al., An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene, 2009. 28(31): pp. 2773–83.Google Scholar
Shi, Y., et al., A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol, 2014. 9(2): pp. 154–62.Google Scholar
Hirsch, F. R. and Bunn, P. A. Jr., EGFR testing in lung cancer is ready for prime time. Lancet Oncol, 2009. 10(5): pp. 432–3.Google Scholar
Zhang, Y. L., et al., The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis. Oncotarget, 2016. 7(48): pp. 78985–93.Google Scholar
Marcoux, N., et al., EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: Clinical outcomes. J Clin Oncol, 2019. 37(4): pp. 278–85.Google Scholar
Paik, P. K., et al., Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component. Mol Cancer Ther, 2012. 11(11): pp. 2535–40.CrossRefGoogle ScholarPubMed
Planchard, D., et al., Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2018. 29(Suppl. 4): pp. iv192–iv237.Google Scholar
Planchard, D., et al., Clinical Practice Living Guidelines – Metastatic Non-Small-Cell Lung Cancer. ESMO Guidelines 2020 [cited November 14, 2021]; www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer.Google Scholar
D’Angelo, S. P., et al., Incidence of EGFR exon 19 deletions and L858 R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol, 2011. 29(15): pp. 2066–70.Google Scholar
National Comprehensive Cancer Network (NCCN), Non-Small Cell Lung Cancer. October 29, 2021 [cited November 14]; Version 7.2021; www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.Google Scholar
Sharma, S. V., et al., Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer, 2007. 7(3): pp. 169–81.Google Scholar
Hirsch, F. R., et al., Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol, 2003. 21(20): pp. 3798–807.Google Scholar
Testa, J. R. and Siegfried, J. M., Chromosome abnormalities in human non-small cell lung cancer. Cancer Res, 1992. 52(9 Suppl.): pp. 2702s–2706s.Google Scholar
Herbst, R. S., Heymach, J. V., and Lippman, S. M., Lung cancer. N Engl J Med, 2008. 359(13): pp. 1367–80.Google Scholar
Yun, C. H., et al., Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell, 2007. 11(3): pp. 217–27.CrossRefGoogle ScholarPubMed
Maemondo, M., et al., Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 2010. 362(25): pp. 2380–8.Google Scholar
Sequist, L. V., et al., Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol, 2013. 31(27): pp. 3327–34.Google Scholar
Kobayashi, Y. and Mitsudomi, T., Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci, 2016. 107(9): pp. 1179–86.Google Scholar
Riess, J. W., et al., Diverse EGFR Exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC. J Thorac Oncol, 2018. 13(10): pp. 1560–8.Google Scholar
Vasconcelos, P., et al., EGFR-A763_Y764insFQEA is a unique exon 20 insertion mutation that displays sensitivity to approved and in-development lung cancer EGFR tyrosine kinase inhibitors. JTO Clin Res Rep, 2020. 1(3): 100051.Google Scholar
Yasuda, H., et al., Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med, 2013. 5(216): 216ra177.Google Scholar
Du, Z., et al., Structure-function analysis of oncogenic EGFR kinase domain duplication reveals insights into activation and a potential approach for therapeutic targeting. Nat Commun, 2021. 12(1): 1382.Google Scholar
Russo, A., et al., Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario. Int J Mol Sci, 2019. 20(6): 1431.Google Scholar
Park, K., et al., Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the CHRYSALIS phase I study. J Clin Oncol, 2021. 39(30): pp. 3391–402.Google Scholar
Park, K., et al., Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol, 2020. 38(Suppl.): 9512.Google Scholar
Ramalingam, S. S., et al., Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study. J Clin Oncol, 2021. 39(15_suppl.): 9014.CrossRefGoogle Scholar
Yang, J. C., et al., Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol, 2015. 16(7): pp. 830–8.Google Scholar
Yang, J. C., et al., Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: A database of 693 cases. J Thorac Oncol, 2020. 15(5): pp. 803–15.Google Scholar
Cho, J. H., et al., Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin Oncol, 2020. 38(5): pp. 488–95.Google Scholar
Morin, M. J., From oncogene to drug: Development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents. Oncogene, 2000. 19(56): pp. 6574–83.Google Scholar
Mok, T. S., et al., Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009. 361(10): pp. 947–57.Google Scholar
Inoue, A., et al., Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol, 2013. 24(1): pp. 54–9.Google Scholar
Yoshioka, H., et al., Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Ann Oncol, 2019. 30(12): pp. 1978–84.Google Scholar
Mitsudomi, T., et al., Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol, 2010. 11(2): pp. 121–8.Google Scholar
Fukuoka, M., et al., Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol, 2011. 29(21): pp. 2866–74.Google Scholar
Douillard, J. Y., et al., First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: A phase-IV, open-label, single-arm study. Br J Cancer, 2014. 110(1): pp. 55–62.Google Scholar
Zhou, C., et al., Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011. 12(8): pp. 735–42.Google Scholar
Rosell, R., et al., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2012. 13(3): pp. 239–46.Google Scholar
Patil, V. M., et al., Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. ESMO Open, 2017. 2(1): e000168.Google Scholar
Kobayashi, S., et al., EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med, 2005. 352(8): pp. 786–92.Google Scholar
Kosaka, T., et al., Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res, 2006. 12(19): pp. 5764–9.Google Scholar
Solca, F., et al., Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther, 2012. 343(2): pp. 342–50.Google Scholar
Hsu, W. H., et al., Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol, 2018. 29(Suppl. 1): pp. i3–i9.Google Scholar
Wu, Y. L., et al., Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet Oncol, 2014. 15(2): pp. 213–22.Google Scholar
Yang, J. C., et al., Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol, 2015. 16(2): pp. 141–51.Google Scholar
Mok, T. S., et al., Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol, 2018. 36(22): pp. 2244–50.Google Scholar
Cross, D. A., et al., AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov, 2014. 4(9): pp. 1046–61.Google Scholar
Soria, J. C., et al., Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med, 2018. 378(2): pp. 113–25.Google Scholar
Yang, J. C., et al., Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA Study Phase II Extension Component. J Clin Oncol, 2017. 35(12): pp. 1288–96.Google Scholar
Goss, G., et al., Osimertinib for pretreated EGFR Thr790 Met-positive advanced non-small-cell lung cancer (AURA2): A multicentre, open-label, single-arm, phase 2 study. Lancet Oncol, 2016. 17(12): pp. 1643–52.Google Scholar
Akamatsu, H., et al., Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial. Cancer Sci, 2018. 109(6): pp. 1930–8.Google Scholar
Ramalingam, S. S., et al., Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med, 2020. 382(1): pp. 41–50.Google Scholar
Cho, B., et al., 1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC. Ann Oncol, 2020. 31: p. S813.CrossRefGoogle Scholar
Lu, S., et al., Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858 R mutations (EGFRm). J Clin Oncol, 2021. 39(15_suppl.): 9013.Google Scholar
Nagasaka, M., et al., Beyond osimertinib: The development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC. J Thorac Oncol, 2021. 16(5): pp. 740–63.Google Scholar
Zhou, Q., et al., CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC. Ann Oncol, 2019. 30: p. v603.Google Scholar
Saito, H., et al., Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): Interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol, 2019. 20(5): pp. 625–35.Google Scholar
Nakagawa, K., et al., Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 2019. 20(12): pp. 1655–69.Google Scholar
Le, X., et al., Dual EGFR-VEGF pathway inhibition: A promising strategy for patients with EGFR-mutant NSCLC. J Thorac Oncol, 2021. 16(2): pp. 205–15.Google Scholar
Yu, H. A., et al., Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: A phase 1/2 single-group open-label trial. JAMA Oncol, 2020. 6(7): pp. 1048–54.Google Scholar
Akamatsu, H., et al., Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M-mutated non-small cell lung cancer previously treated with epidermal growth factor receptor-tyrosine kinase inhibitor: West Japan Oncology Group 8715 L Phase 2 randomized clinical trial. JAMA Oncol, 2021. 7(3): pp. 386–94.Google Scholar
Kenmotsu, H., et al., Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717 L study. Ann Oncol, 2021. 32: pp. S1283–S1346.Google Scholar
Noronha, V., et al., Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol, 2020. 38(2): pp. 124–36.Google Scholar
Hosomi, Y., et al., Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 Study. J Clin Oncol, 2020. 38(2): pp. 115–23.Google Scholar
Wu, Q., et al., First-generation EGFR-TKI plus chemotherapy versus EGFR-TKI alone as first-line treatment in advanced NSCLC with EGFR activating mutation: A systematic review and meta-analysis of randomized controlled trials. Front Oncol, 2021. 11: 598265.Google Scholar
Planchard, D., et al., 1401P Osimertinib plus platinum/pemetrexed in newly-diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study. Ann Oncol, 2020. 31: p. S888.Google Scholar
Kelly, K., et al., Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): A randomized, double-blind, phase III trial. J Clin Oncol, 2015. 33(34): pp. 4007–14.Google Scholar
Goss, G. D., et al., Gefitinib versus placebo in completely resected non-small-cell lung cancer: Results of the NCIC CTG BR19 study. J Clin Oncol, 2013. 31(27): pp. 3320–6.Google Scholar
Wu, Y.-L., et al., CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation – Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial. American Society of Clinical Oncology, 2020. 38(15_suppl.): 9005.Google Scholar
Wu, Y.-L., et al., Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med, 2020. 383(18): pp. 1711–23.Google Scholar
Jorge, S. E., et al., EGFR exon 20 insertion mutations display sensitivity to Hsp90 inhibition in preclinical models and lung adenocarcinomas. Clin Cancer Res, 2018. 24(24): pp. 6548–55.Google Scholar
Yasuda, H., Kobayashi, S., and Costa, D. B., EGFR exon 20 insertion mutations in non-small-cell lung cancer: Preclinical data and clinical implications. Lancet Oncol, 2012. 13(1): pp. e23–31.Google Scholar
Vasconcelos, P., et al., Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations. JTO Clin Res Rep, 2021. 2(3): 100105.Google Scholar
Kobayashi, I. S., et al., EGFR-D770>GY and other rare EGFR exon 20 insertion mutations with a G770 equivalence are sensitive to dacomitinib or afatinib and responsive to EGFR exon 20 insertion mutant-active inhibitors in preclinical models and clinical scenarios. Cells, 2021. 10(12): 3561.Google Scholar
Kosaka, T., et al., Response heterogeneity of EGFR and HER2 exon 20 insertions to covalent EGFR and HER2 inhibitors. Cancer Res, 2017. 77(10): pp. 2712–21.Google Scholar
Friedlaender, A., et al., EGFR and HER2 exon 20 insertions in solid tumours: From biology to treatment. Nat Rev Clin Oncol, 2022. 19(1): pp. 51–69.Google Scholar
Meador, C. B., Sequist, L. V., and Piotrowska, Z., Targeting EGFR exon 20 insertions in non-small cell lung cancer: Recent advances and clinical updates. Cancer Discov, 2021. 11(9): pp. 2145–57.Google Scholar
Gonzalvez, F., et al., Mobocertinib (TAK-788): A targeted inhibitor of egfr exon 20 insertion mutants in non-small cell lung cancer. Cancer Discov, 2021. 11(7): pp. 1672–87.Google Scholar
Riely, G. J., et al., Activity and safety of mobocertinib (TAK-788) in previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations from a phase i/ii trial. Cancer Discov, 2021. 11(7): pp. 1688–99.Google Scholar
Udagawa, H., et al., TAS6417/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase inhibitor with a broad spectrum of preclinical activity against clinically relevant EGFR mutations. Mol Cancer Res, 2019. 17(11): pp. 2233–43.Google Scholar
Robichaux, J. P., et al., Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med, 2018. 24(5): pp. 638–46.Google Scholar
Yun, J., et al., Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR exon 20 insertion-driven NSCLC. Cancer Discov, 2020. 10(8): pp. 1194–209.Google Scholar
Vijayaraghavan, S., et al., Amivantamab (JNJ-61186372), an Fc fnhanced EGFR/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte/macrophage trogocytosis. Mol Cancer Ther, 2020. 19(10): pp. 2044–56.Google Scholar
Kobayashi, S., et al., EGFR mutation and resistance of non–small-cell lung cancer to gefitinib. N Engl J Med, 2005. 352(8): pp. 786–92.Google Scholar
Nguyen, K.-S. H., Kobayashi, S., and Costa, D. B., Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer, 2009. 10(4): pp. 281–9.Google Scholar
Niederst, M. J., et al., RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nature Communications, 2015. 6(1): 6377.Google Scholar
Piper-Vallillo, A. J., Sequist, L. V., and Piotrowska, Z., Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib: A review. J Clin Oncol, 2020: Jco1903123.Google Scholar
Pao, W. and Chmielecki, J., Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer, 2010. 10(11): pp. 760–74.Google Scholar
Yun, C. H., et al., The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA, 2008. 105(6): pp. 2070–5.Google Scholar
Wu, S.-G. and Shih, J.-Y., Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer. Mol Cancer, 2018. 17(1): 38.Google Scholar
Ramalingam, S. S., et al., Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med, 2019. 382(1): pp. 41–50.Google Scholar
Passaro, A., et al., Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer, 2021. 2(4): pp. 377–91.Google Scholar
Piotrowska, Z. and Hata, A. N., Resistance to first-line osimertinib in EGFR-mutant NSCLC: Tissue is the issue. Clin Cancer Res, 2020. 26(11): pp. 2441–3.Google Scholar
Schoenfeld, A. J., et al., Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer. Clin Cancer Res, 2020. 26(11): pp. 2654–63.Google Scholar
Oxnard, G. R., et al., Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol, 2018. 4(11): pp. 1527–34.Google Scholar
Socinski, M. A., et al., Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med, 2018. 378(24): pp. 2288–301.Google Scholar
Reck, M., et al., 1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations. Ann Oncol, 2020. 31: pp. S837–S838.Google Scholar
Rangachari, D., et al., EGFR-mutated lung cancers resistant to osimertinib through EGFR C797S respond to first-generation reversible EGFR inhibitors but eventually acquire EGFR T790M/C797S in preclinical models and clinical samples. J Thorac Oncol, 2019. 14(11): pp. 1995–2002.Google Scholar
Tricker, E. M., et al., Combined EGFR/MEK inhibition prevents the emergence of resistance in EGFR-mutant lung cancer. Cancer Discov, 2015. 5(9): pp. 960–71.Google Scholar
Rotow, J. K., et al., Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC). J Clin Oncol, 2020. 38(15_suppl.): p. 9507.Google Scholar
Riely, G., et al., P1.01-81 phase 3 study of pemetrexed-platinum with or without pembrolizumab for tki-resistant/EGFR-mutated advanced NSCLC: KEYNOTE-789. J Thorac Oncol, 2018. 13(10): p. S494.Google Scholar
Oxnard, G. R., et al., TATTON: A multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol, 2020. 31(4): pp. 507–16.Google Scholar
Li, S., et al., Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell, 2005. 7(4): pp. 301–11.Google Scholar
Bauml, J., et al., Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. J Clin Oncol, 2021. 39(15_suppl.): p. 9006.Google Scholar
Shu, C. A., et al., Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2. Ann Oncol, 2021. 32: pp. S949–S1039.Google Scholar
Chari, R. V., Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc Chem Res, 2008. 41(1): pp. 98–107.Google Scholar
Beck, A., et al., Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov, 2017. 16(5): pp. 315–37.Google Scholar
Camidge, D. R., et al., Phase I study of 2- or 3-week dosing of telisotuzumab vedotin, an antibody-drug conjugate targeting c-Met, monotherapy in patients with advanced non-small cell lung carcinoma. Clin Cancer Res, 2021. 27(21): pp. 5781–92.Google Scholar
Jänne, P. A., et al., Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discov, 2021. 12(1): pp. 74–89.Google Scholar
Janne, P. A., et al., HERTHENA-Lung01: A randomized phase 2 study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC. J Clin Oncol, 2021. 39(15_suppl.): TPS9139.Google Scholar
Sankyo, Daiichi, Press release: Patritumab Deruxtecan Granted US FDA Breakthrough Therapy Designation in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer. 2021; www.daiichisankyo.com/files/news/pressrelease/pdf/202112/20211223_E1.pdf.Google Scholar
Schalm, S. S., et al., 1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC. Ann Oncol, 2020. 31: p. S839.Google Scholar
Rossi, S., et al., Uncommon single and compound EGFR mutations: Clinical outcomes of a heterogeneous subgroup of NSCLC. Curr Probl Cancer, 2022. 46(1): 100787.Google Scholar
Reck, M., et al., Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol, 2019. 37(7): pp. 537–46.Google Scholar
Mok, T. S. K., et al., Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. Lancet, 2019. 393(10183): pp. 1819–30.Google Scholar
Garassino, M. C., et al., Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol, 2020. 21(3): pp. 387–97.Google Scholar
Gandhi, L., et al., Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med, 2018. 378(22): pp. 2078–92.Google Scholar
Gadgeel, S., et al., Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol, 2020. 38(14): pp. 1505–17.Google Scholar
Paz-Ares, L., et al., Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med, 2018. 379(21): pp. 2040–51.Google Scholar
Paz-Ares, L., et al., A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: Protocol-specified final analysis of KEYNOTE-407. J Thorac Oncol, 2020. 15(10): pp. 1657–69.Google Scholar
Reck, M., et al., Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med, 2016. 375(19): pp. 1823–33.Google Scholar
Garon, E. B., et al., Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: Results from the phase I KEYNOTE-001 study. J Clin Oncol, 2019. 37(28): pp. 2518–27.Google Scholar
Herbst, R. S., et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet, 2016. 387(10027): pp. 1540–50.Google Scholar
Borghaei, H., et al., Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med, 2015. 373(17): pp. 1627–39.Google Scholar
Rittmeyer, A., et al., Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet, 2017. 389(10066): pp. 255–65.Google Scholar
Rizvi, H., et al., Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol, 2018. 36(7): pp. 633–41.Google Scholar
Lee, C. K., et al., Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non–small cell lung carcinoma: A systematic review and meta-analysis. JAMA Oncol, 2018. 4(2): pp. 210–16.Google Scholar
Mazieres, J., et al., Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: Results from the IMMUNOTARGET registry. Ann Oncol, 2019. 30(8): pp. 1321–8.Google Scholar
Lisberg, A., et al., A phase ii study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC. J Thorac Oncol, 2018. 13(8): pp. 1138–45.Google Scholar
Lu, S., et al., VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy. Ann Oncol, 2022. 33(1): pp. 112–3.Google Scholar
Antonia, S. J., et al., Durvalumab after chemoradiotherapy in stage III non–small-cell lung Cancer. N Engl J Med, 2017. 377(20): pp. 1919–29.Google Scholar
Dong, Z. Y., et al., EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. Oncoimmunology, 2017. 6(11): e1356145.Google Scholar
Gainor, J. F., et al., EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non–small cell lung cancer: A retrospective analysis. Clin Cancer Res, 2016. 22(18): pp. 4585–93.Google Scholar
Budczies, J., et al., Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. Cancer Immunol Immunother, 2021. 71(2): pp. 251–65.Google Scholar
Streicher, K., et al., Increased CD73 and reduced IFNG signature expression in relation to response rates to anti-PD-1(L1) therapies in EGFR-mutant NSCLC. J Clin Oncol, 2017. 35(15_suppl.): p. 11505.Google Scholar
Park, L. C., et al., Immunologic and clinical implications of CD73 expression in non-small cell lung cancer (NSCLC). J Clin Oncol, 2018. 36(15_suppl.): p. 12050.Google Scholar
Passarelli, A., et al., Targeting immunometabolism mediated by CD73 pathway in EGFR-mutated non-small cell lung cancer: A new hope for overcoming immune resistance. Front Immunol, 2020. 11: 1479.Google Scholar
Yu, S., et al., Immunotherapy strategy of EGFR mutant lung cancer. Am J Cancer Res, 2018. 8(10): pp. 2106–15.Google Scholar
Schoenfeld, A. J., et al., Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol, 2019. 30(5): pp. 839–44.Google Scholar
Yang, J. C., et al., Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-positive NSCLC following previous EGFR TKI therapy: CAURAL Brief Report. J Thorac Oncol, 2019. 14(5): pp. 933–9.Google Scholar
Hu, C., et al., Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis. Cancer, 2006. 106(9): pp. 1998–2004.Google Scholar
Ge, M., et al., High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases. J Neurooncol, 2017. 135(2): pp. 413–18.CrossRefGoogle ScholarPubMed
Soon, Y. Y., et al., EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: A systematic review and meta-analysis. Radiother Oncol, 2015. 114(2): pp. 167–72.Google Scholar
Magnuson, W. J., et al., Management of brain metastases in tyrosine kinase inhibitor–naïve epidermal growth factor receptor–mutant non–small-cell lung cancer: A retrospective multi-institutional analysis. J Clin Oncol, 2017. 35(10): pp. 1070–7.Google Scholar
Xu, Q., et al., Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs. J Thorac Oncol, 2018. 13(9): pp. 1383–92.Google Scholar
Wang, X. and Zeng, M., First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332). J Clin Oncol, 2020. 38(15_suppl.): p. 9508.Google Scholar
Ballard, P., et al., Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res, 2016. 22(20): pp. 5130–40.Google Scholar
Mok, T. S., et al., Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med, 2016. 376(7): pp. 629–40.Google Scholar
Goss, G., et al., CNS response to osimertinib in patients with T790M-positive advanced NSCLC: Pooled data from two phase II trials. Ann Oncol, 2018. 29(3): pp. 687–93.Google Scholar
Yamaguchi, H., et al., A phase II study of osimertinib for radiotherapy-naive central nervous system metastasis from NSCLC: Results for the T790M cohort of the OCEAN study (LOGIK1603/WJOG9116 L). J Thorac Oncol, 2021. 16(12): pp. 2121–32.Google Scholar
Wu, Y.-L., et al., CNS efficacy of osimertinib in patients with T790M-positive advanced non–small-cell lung cancer: Data from a randomized phase III trial (AURA3). J Clin Oncol, 2018. 36(26): pp. 2702–9.Google Scholar
Yang, J. C. H., et al., Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM study. J Clin Oncol, 2020. 38(6): pp. 538–47.Google Scholar
Lee, J., et al., Osimertinib improves overall survival in patients with EGFR-mutated NSCLC with leptomeningeal metastases regardless of T790M mutational status. J Thorac Oncol, 2020. 15(11): pp. 1758–66.Google Scholar
Ahn, M.-J., et al., Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: The AURA leptomeningeal metastases analysis. J Thorac Oncol, 2020. 15(4): pp. 637–48.Google Scholar
Zhai, X., et al., Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: A retrospective study. Radiat Oncol, 2021. 16(1): 233.Google Scholar
Zeng, Y., et al., The value of local consolidative therapy in osimertinib-treated non-small cell lung cancer with oligo-residual disease. Radiat Oncol, 2020. 15(1): 207.Google Scholar
Laurie, S. A., et al., Canadian consensus: Oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer. Curr Oncol, 2019. 26(1): pp. e81–e93.Google Scholar
Shukuya, T., et al., Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Cancer, 2011. 74(3): pp. 457–61.Google Scholar
Weickhardt, A. J., et al., Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol, 2012. 7(12): pp. 1807–14.Google Scholar
Di Noia, V., et al., Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: Novel targeted agents and combination strategies. ESMO Open, 2021. 6(6): 100280.Google Scholar
Le, X., et al., Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. Clin Cancer Res, 2018. 24(24): pp. 6195–203.Google Scholar
Mu, Y., et al., Clinical modality of resistance and subsequent management of patients with advanced non-small cell lung cancer failing treatment with osimertinib. Target Oncol, 2019. 14(3): pp. 335–42.Google Scholar
Cortellini, A., et al., Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: A multicenter study of clinicians’ attitudes. Clin Transl Oncol, 2020. 22(6): pp. 844–51.Google Scholar
Mulvenna, P., et al., Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): Results from a phase 3, non-inferiority, randomised trial. Lancet, 2016. 388(10055): pp. 2004–14.Google Scholar
Zhou, C., et al., Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer: A phase 1/2 open-label nonrandomized clinical trial. JAMA Oncol, 2021: e214761.Google Scholar
Gomez, D. R., et al., Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol, 2019. 37(18): pp. 1558–65.Google Scholar
Douillard, J. Y., et al., Gefitinib treatment in EGFR mutated caucasian NSCLC: Circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol, 2014. 9(9): pp. 1345–53.Google Scholar
Wu, Y. L., et al., Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies. Lung Cancer, 2018. 126: pp. 1–8.Google Scholar
Qiu, M., et al., Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: A meta-analysis. Cancer Epidemiol Biomarkers Prev, 2015. 24(1): pp. 206–12.Google Scholar
Jenkins, S., et al., Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non-small cell lung cancer. J Thorac Oncol, 2017. 12(7): pp. 1061–70.Google Scholar
Thress, K. S., et al., EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer, 2015. 90(3): pp. 509–15.Google Scholar
Papadimitrakopoulou, V. A., et al., Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. Cancer, 2020. 126(2): pp. 373–80.Google Scholar
Rolfo, C., et al., Liquid biopsy for advanced non-small cell lung cancer (NSCLC): A statement paper from the IASLC. J Thorac Oncol, 2018. 13(9): pp. 1248–68.Google Scholar
Wu, Y. L., et al., First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: Analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol, 2015. 26(9): pp. 1883–9.Google Scholar
US Food and Drug Administration. cobas EGFR Mutation Test v2. June 2, 2016 [cited November 1, 2021]; www.fda.gov/drugs/resources-information-approved-drugs/cobas-egfr-mutation-test-v2.Google Scholar
Sacher, A. G., et al., Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol, 2016. 2(8): pp. 1014–22.Google Scholar
Oxnard, G. R., et al., Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol, 2016. 34(28): pp. 3375–82.Google Scholar
Remon, J., et al., Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNA. Ann Oncol, 2017. 28(4): pp. 784–90.Google Scholar
Sundaresan, T. K., et al., Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clin Cancer Res, 2016. 22(5): pp. 1103–10.Google Scholar
Gray, J. E., et al., Tissue and plasma EGFR mutation analysis in the FLAURA trial: Osimertinib versus comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer. Clin Cancer Res, 2019. 25(22): pp. 6644–52.Google Scholar
Guo, K., et al., Detection of epidermal growth factor receptor (EGFR) mutations from preoperative circulating tumor DNA (ctDNA) as a prognostic predictor for stage I-III non-small cell lung cancer (NSCLC) patients with baseline tissue EGFR mutations. Transl Lung Cancer Res, 2021. 10(7): pp. 3213–25.Google Scholar
Accessibility standard: Unknown
Why this information is here
This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.Accessibility Information
Accessibility compliance for the HTML of this Element is currently unknown
and may be updated in the future.
- 1
- Cited by